Publications

Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.

Patel SM. et al, (2024), Circulation

Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns

Levin A. et al, (2024), Kidney International, 105, 684 - 701

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group None., (2024), Kidney Int, 105, S117 - S314

EFFECTS OF EMPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM JAPAN: EXPLORATORY ANALYSES FROM EMPA-KIDNEY

HERRINGTON W., (2024), Clinical and Experimental Nephrology

[2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes].

Marx N. et al, (2024), G Ital Cardiol (Rome), 25, e1 - e103

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith C. et al, (2024), The Lancet Diabetes and Endocrinology

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2023), Lancet Diabetes Endocrinol, 11, 905 - 914

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

Mark PB. et al, (2023), Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 38, 2444 - 2455

UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.

Roddick AJ. et al, (2023), BMC Nephrol, 24

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.

Marx N. et al, (2023), Eur Heart J, 44, 4043 - 4140

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.

Writing Group for the CKD Prognosis Consortium None. et al, (2023), JAMA, 330, 1266 - 1277

SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.

SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration None., (2023), Eur Heart J, 44, 2544 - 2556

The authors reply.

Chapman D. et al, (2023), Kidney Int, 104, 201 - 202

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

Inker LA. et al, (2023), Nat Med

Empagliflozin in Patients with Chronic Kidney Disease. Reply.

Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.

Harper C. et al, (2023), Heart

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Cookies on this website

Publications